Littleton, CO, October 27, 2011 --(PR.com
)-- Novus Biologicals announced today the release of new LDL Receptor (NBP1-78159) and VLDL Receptor (NBP1-78162) antibodies.
LDL and VLDL Receptors are similar cell-surface receptor proteins which mediate endocytosis of cholesterol-rich lipoproteins. Both receptors are critical to the lipid and cholesterol metabolism required for proper cellular homeostasis, and defects with these receptors have been implicated in a wide variety of diseases.
Novus new LDL Receptor (NBP1-78159) and VLDL Receptor (NBP1-78162) antibodies have been thoroughly validated for use in Western blot and immunofluorescence staining on human and bovine samples, with testing data available on the product datasheets. Additionally, each has been cited in multiple published articles.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.